Description
(AWP Alliance News) - Novartis' third-quarter 2026 net income dropped 70% from a year earlier to USD 1.2 billion. Operating income fell 59% to USD 1.84 billion, mainly due to higher research and development expenses, including a USD 1.9 billion partial impairment of del-desiran.
Net sales rose to USD 14.52 billion, with volume growth partly offset by generic competition and lower pricing. In pipeline updates, del-desiran missed its primary endpoint in a Phase III myotonic dystrophy trial, while remibrutinib met its primary endpoint in two Phase III relapsing multiple sclerosis trials.
https://docs.publicnow.com/C0D67E9F365BA0AC9F49D6317EF5A1184DEA6470
Disclaimer: This news brief was created using generative artificial intelligence. Novartis AG published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.
